Dow Jones received a payment from EQS/DGAP to publish this press release.
EQS-News / 12/12/2016 / 12:07 UTC+8
For immediate release 10 December 2016
*Commencement of Strategic Cooperation by CEO of Intuitive Surgical, a
Global Leader in the Field of Robotic-Assisted Minimally Invasive Surgery,
with Fosun Pharma*
?December 10 2016, Hong Kong?On the morning of 10 December 2016, Shanghai
Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code:
600196.SH, 02196.HK) held Fosun Pharma & Intuitive Surgical, Inc. Strategic
Cooperation Press Conference and Artificial Intelligence-assisted Precision
Medicine Summit at Shanghai Ruijin Hotel. Witnessed by Huang Hong, Secretary
of Party Committee of Shanghai Municipal Commission of Health and Family
Planning, Xulai, Deputy Director General of Shanghai Food and Drug
Administration, Zhao Zilin, Chairman of China Association of Medical
Equipment, Wang Longxing, Chairman of Shanghai Pharmaceutical Association
and Guo Guangchang, Chairman of Fosun Group and Non-executive Director of
Fosun Pharma, Chen Qiyu, Chairman of Fosun Pharma and Dr. Gary Guthart,
President and Chief Executive Officer of Intuitive Surgical, Inc.
(hereinafter referred to as "Intuitive Surgical") announced on site the
official commencement of their strategic cooperation in China. The two
parties will jointly invest US100 million to establish a joint venture in
Shanghai, which will mainly engage in research, production and sale of
innovative robotic-assisted catheter-based technology for early-stage
diagnosis and treatment of lung cancer. This will be a new product line
separate from the da Vinci(R) Surgical System products developed by
Intuitive Surgical.
"Chindex Medical Limited, a holding subsidiary of Fosun Pharma, is a
distribution partner for Intuitive Surgical's da Vinci Surgical Systems in
China. Our collaboration with Fosun Pharma started in 2011, and we are proud
to be expanding our relationship to explore new and innovative healthcare
solutions together," said Dr. Gary Guthart, President and CEO of Intuitive
Surgical. "It is the first time we are establishing a R&D and production
center in China. We are looking forward to making this important long-term
commitment to China."
The joint venture will be engaging in the development of medical tools for
diagnosis and treatment of lung cancer, both domestically and
internationally, in a more convenient, efficient and comfortable way with
its motto of "domestic manufacture, joint R&D and global sales". Initial
product developments will be applicable to the early diagnosis of lung
cancer, and whereas R&D work at a later stage will be focused on early and
effective treatment of lung cancer.
Currently, lung cancer in China has a mortality rate that is ranked first
among all kinds of cancer. Lung cancer is also recognized as the top killer
among all cancers globally, with one of five fatal cancer cases being lung
cancer.
Chen Qiyu, Chairman of Fosun Pharma, mentioned that "Lung cancer is one of
the most common cancers in the world, particularly in China, so the early
diagnosis and treatment are extremely important. Intuitive Surgical is a
great company driven by cutting-edge technology. We hope that the costs on
diagnosis and treatment of Chinese patients suffering from lung cancer would
be reduced through the localization of R&D, manufacture and sales by
establishing the joint venture company with Intuitive Surgical. We expect
that the cooperation will allow doctors to be equipped with innovative
medical tools for precise diagnosis in order to upgrade the standard of
medical treatment. We're confident that the innovative products developed by
the new joint venture will be marked to China rapidly, and then further
benefit patients across the globe. "
Mr. Guo Guangchang said, "Since the very beginning of Fosun Group's
establishment, pharmaceutical and healthcare have been one of our key
segments. After developing for more than 20 years, Fosun healthcare sector
is now a leader in China's pharmaceutical and healthcare industry.
Healthcare is a crucial cog for Fosun's strategy of focusing on demand for
wealth, health and happiness from middle-class families. Since precision
medicine is the future direction of healthcare industry, we hope that we can
integrate the cutting-edge R&D capabilities of Intuitive Surgical with the
extensive resources disposable of Fosun Pharma to create precision medical
closed loop, so as to improve health quality and health indicators of the
increasing number of patients who suffer from lung cancer at home and
abroad."
On the day, Dr. Gao Changqing from the General Hospital of the People's
Liberation Army and Dr. Bai Chunxue, Chairman of Chinese Alliance Against
Lung Cancer (CAALC) and Chairman of Shanghai Respiratory Research Institute
also attended the forum and delivered speeches for the guests on
cutting-edge topics such as the future of robotic-assisted surgery and how
to prevent and cure lung cancer in the age of internet of things.
Meanwhile, a charitable robotic-assisted pancreatic tumor resection
performed with a da Vinci System conducted by Professor Peng Chenghong from
Ruijin Hospital was simulcast at the forum. As witnessed by the guests,
Professor Peng has successfully performed the surgery on the patient. Later,
Mr. Guo Guangchang and Dr. Gary Guthart accompanied by Dr. Shen Baiyong,
Vice President of Ruijin Hospital, offered their congratulations to
Professor Peng on his success in operation at Ruijin Hospital.
*About Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.*
Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun
Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare Group in
the PRC. Fosun Pharma strategically covers important segments of the
healthcare industry value-chain, including pharmaceutical manufacturing and
R&D, healthcare services, medical diagnosis, medical devices manufacturing
and agent, as well as pharmaceutical distribution and retail, making
contribution to improving people's health. Fosun Pharma maintains a National
Recognized Enterprise Technology Centre and a highly capable international
R&D team, focusing on innovation and research of therapeutic areas including
cardiovascular system, central nervous system, blood system, metabolism and
alimentary system, anti-infection and anti-tumor. With its commitment to
innovation for good health and creating a better future, Fosun Pharma will
continue insisting on the strategic development approach of "organic growth
, external expansion and integrated development", striving to be one of the
leading enterprises in the global healthcare market.
_The press release is distributed by Wonderful Sky Financial Group on behalf
of Fosun Pharmaceutical (Group) Co. Ltd._
*For more information, please contact:*
Fosun Pharmaceutical (Group) Co. Ltd.
Cathy Wang
Tel: (+86) 021-3398 7122
Fax: (+86) 021-3398 7020
Email: wangpuyu@fosunpharma.com
Wonderful Sky Financial Group Limited
Iris Au Yeung / Cici Liu/ Cherish Xu/ Curry Wang
Tel:(852) 3970 2108 / 3970 2107/ 3757 4715/ 3970 0133
Fax:(852) 2865 1638
Email:po@wsfg.hk / fosunpharma@wsfg.hk
Document: http://n.eqs.com/c/fncls.ssp?u=FGRDFHJPNP [1]
Document title: Commencement of Strategic Cooperation by CEO of Intuitive
Surgical, a Global Leader in the Field of Robotic-Assisted Minimally
Invasive Surgery, with Fosun Pharma
Key word(s): Alliance
12/12/2016 Dissemination of a Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Media archive at www.todayir.com
528637 12/12/2016
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=67d1131d389484c8dcf30b552b9df531&application_id=528637&site_id=vwd&application_name=news
(END) Dow Jones Newswires
December 11, 2016 23:09 ET (04:09 GMT)
